Wolfe Research analyst Rod Lache downgrades Sensata Technologies (NYSE:ST) from Outperform to Peer Perform.
Ultragenyx To Present Setrusumab Update At ASBMR 2023 Including New Data From Phase 2/3 Orbit Study In Osteogenesis Imperfecta
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that data from its ongoing late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta (OI) will be presented at the American Society for Bone
